

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4765737

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ELSIE MELSOPP	02/17/2017
JACK LAWRENCE JAMES	02/17/2017
RECEIVING PARTY DATA	
Name:	AAIPHARMA SERVICES CORP.
Street Address:	2320 SCIENTIFIC PARK DRIVE
City:	WILMINGTON
State/Country:	NORTH CAROLINA
Postal Code:	28405
PROPERTY NUMBERS Total: 1	
Property Type	Number
PCT Number:	US2016033567
CORRESPONDENCE DATA	
Fax Number:	(646)219-6229
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(646)973-2500
Email:	HGPatentDocket@hglaw.com
Correspondent Name:	HALEY GUILIANO LLP
Address Line 1:	75 BROAD STREET, SUITE 1000
Address Line 4:	NEW YORK, NEW YORK 10004
ATTORNEY DOCKET NUMBER:	107042-0021-WO1
NAME OF SUBMITTER:	LILY JIANG
SIGNATURE:	/Lily Jiang/
DATE SIGNED:	01/08/2018
Total Attachments: 5	
source=107042-0021-WO1 signed PCT signed Assignment from Melsopp and James to AAIPS#page1.tif	
source=107042-0021-WO1 signed PCT signed Assignment from Melsopp and James to AAIPS#page2.tif	
source=107042-0021-WO1 signed PCT signed Assignment from Melsopp and James to AAIPS#page3.tif	
source=107042-0021-WO1 signed PCT signed Assignment from Melsopp and James to AAIPS#page4.tif	
source=107042-0021-WO1 signed PCT signed Assignment from Melsopp and James to AAIPS#page5.tif	

PCT
ASSIGNMENT

We,

- (1) Elsie Melsopp, and
- (2) Jack Lawrence James.

residing, respectively, at

- (1) 7408 Tillson Court
Wilmington, North Carolina 28411
United States of America, and
- (2) 5724 Sidbury Road
Castle Hayne, North Carolina 28429
United States of America.

for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to and do hereby assign, sell and transfer to AAIPHARMA SERVICES CORP. ("AAIPharma"), an entity organized and existing under the laws of the State of Delaware and having an office and a place of business at 2320 Scientific Park Drive, Wilmington, North Carolina 28405, USA, its successors and assigns: (1) the entire right, title and interest in all countries throughout the world in and to any and all our inventions and discoveries disclosed in our International Patent Application, filed under the Patent Cooperation Treaty in the United States Receiving Office (RO/US) on May 20, 2016, assigned application number PCT/US2016/033567, entitled: "EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF LEVETIRACETAM", and designating all PCT member states, including Albania (AL), Algeria (DZ), Angola (AO), Antigua & Barbuda (AG), Armenia (AM), Australia (AU), Austria (AT), Azerbaijan (AZ), Bahrain (BH), Barbados (BB), Belarus (BY), Belgium (BE), Belize (BZ), Benin (BJ), Bosnia and Herzegovina (BA), Botswana (BW), Brazil (BR), Brunei Darussalam (BN), Bulgaria (BG), Burkina Faso (BF), Cameroon (CM), Canada (CA), Central African Republic (CF), Chad (TD), Chile (CL), China (CN), Colombia (CO), Comoros (KM), Congo (CG), Costa Rica (CR), Côte d'Ivoire (CI), Croatia (HR), Cuba (CU), Cyprus (CY), Czech Republic (CZ), Democratic People's Republic of Korea (KP), Denmark (DK), Dominica (DM), Dominican Republic (DO), Ecuador (EC), Egypt (EG), El Salvador (SV), Equatorial Guinea (GQ), Estonia (EE), Finland (FI), France (FR), Gabon (GA), Gambia (GM), Georgia (GE), Germany (DE), Ghana (GH), Greece (GR), Grenada (GD), Guatemala (GT), Guinea (GN), Guinea Bissau (GW), Honduras (HN), Hungary (HU), Iceland (IS), India (IN), Indonesia

(ID), Iran (IR), Ireland (IE), Israel (IL), Italy (IT), Japan (JP), Kazakhstan (KZ), Kenya (KE), Kyrgyzstan (KG), Lao People's Democratic Republic (LA), Latvia (LV), Lesotho (LS), Liberia (LR), Libyan Arab Jamahiriya (LY), Liechtenstein (LI), Lithuania (LT), Luxembourg (LU), Madagascar (MG), Malawi (MW), Malaysia (MY), Mali (ML), Malta (MT), Mauritania (MR), Mexico (MX), Monaco (MC), Mongolia (MN), Montenegro (ME), Morocco (MA), Mozambique (MZ), Namibia (NA), Netherlands (NL), New Zealand (NZ), Nicaragua (NI), Niger (NE), Nigeria (NG), Norway (NO), Oman (OM), Panama (PA), Papua New Guinea (PG), Peru (PE), the Philippines (PH), Poland (PL), Portugal (PT), Qatar (QA), Republic of Korea (KR), Republic of Moldova (MD), Romania (RO), Russian Federation (RU), Rwanda (RW), Saint Kitts and Nevis (KN), Saint Lucia (LC), Saint Vincent and the Grenadines (VC), San Marino (SM), Sao Tome and Principe (ST), Saudi Arabia (SA), Senegal (SN), Serbia (RS), Seychelles (SC), Sierra Leone (SL), Singapore (SG), Slovakia (SK), Slovenia (SI), South Africa (ZA), Spain (ES), Sri Lanka (LK), Sudan (SD), Swaziland (SZ), Sweden (SE), Switzerland (CH), Syrian Arab Republic (SY), Tajikistan (TJ), Thailand (TH), The former Yugoslav Republic of Macedonia (MK), Togo (TG), Trinidad and Tobago (TT), Tunisia (TN), Turkey (TR), Turkmenistan (TM), Uganda (UG), Ukraine (UA), United Arab Emirates (AE), United Kingdom (GB), United Republic of Tanzania (TZ), United States of America (US), Uzbekistan (UZ), Viet Nam (VN), Zambia (ZM) and Zimbabwe (ZW), and all other PCT member states, including any renewals, revivals, reissues, reexaminations, extensions, continuations, and divisions thereof, and any substitute applications therefore; (2) the full and complete right to file patent applications in the name of AAIPharma, its designee, or in our names at AAIPharma, or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patent which may issue on the aforesaid inventions, discoveries and applications in any country of the world and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in and to all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the following priority application:

<u>Application No.</u>	<u>Country</u>	<u>Filing Date</u>
62/165,812	United States of America	May 22, 2015
15/160,424	United States of America	May 20, 2016

and all rights of priority in any country of the world deriving from the above-identified International Patent Application.

We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in any country throughout the world to AAIPharma as

the assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by us had this assignment, sale and transfer not been made.

We agree, at any time, upon the request of AAIPharma to execute and to deliver to AAIPharma any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.


We further agree, at any time, upon request of AAIPharma to execute and to deliver to AAIPharma such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect any and all rights of AAIPharma under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

It is our intention that this Assignment be effective and all rights transferred herein shall be considered to have vested in AAIPharma no later than May 22, 2015, the date of the earliest priority chain.

ASSIGNOR:

Elsie Melsopp
Elsie Melsopp (1)

On this 17th day of February, 2017, Elsie Melsopp personally appeared before me, a Notary Public in and for the state of North Carolina and executed the foregoing Assignment and duly acknowledged to me that such Assignment was executed for the uses and purposes therein expressed.




Ruth W. Dye
Notary Public

My commission expires June 26, 2019.

ASSIGNOR:

Jack Lawrence James
Jack Lawrence James (2)

On this 17th day of February, 2017, Jack Lawrence James personally appeared before me, a Notary Public in and for the state of North Carolina and executed the foregoing Assignment and duly acknowledged to me that such Assignment was executed for the uses and purposes therein expressed.




Ruth W. Dye
Notary Public

My commission expires June 26, 2019.


ACKNOWLEDGEMENT OF ASSIGNEE:

I hereby acknowledge the foregoing executed Assignment on behalf of AAIPHARMA SERVICES CORP.

By:


Name: R. Scott Warner
Title: VP Legal and Asst. Secretary

On this 17th day of February, 2017, R. Scott Warner personally appeared before me, a Notary Public in and for the state of North Carolina, and duly acknowledged the executed Assignment on behalf of the Assignee.




Notary Public

My commission expires June 26, 2019.